CUPERTINO, Calif., Sept. 5, 2017 /PRNewswire/ -- DURECT Corporation
(Nasdaq: DRRX) announced today that management is scheduled to
present at two upcoming investment conferences.
- James E. Brown, President and
CEO, will present at the Rodman & Renshaw Global Investment
Conference on Tuesday, September 12
at 12:30 p.m. Eastern time. The
conference is being held at the Lotte New York Palace Hotel in
New York City. A live audio
webcast of the presentation will be available by accessing
http://wsw.com/webcast/rrshq27/drrx.Management will also be
available for one-on-one meetings at this conference on
Tuesday, September 12; interested
institutional investors should request a one-on-one meeting through
the conference coordinators.
- James E. Brown, President and
CEO, will also present at the Cantor Fitzgerald Global Healthcare
Conference on Monday, September 25 at
3:00 pm Eastern Time. The conference
is being held at the InterContinental New York Barclay Hotel. A
live audio webcast of the presentation will be available by
accessing http://wsw.com/webcast/cantor6/drrx. Management will also
be available for one-on-one meetings at this conference on
Monday, September 25; interested
institutional investors should request a one-on-one meeting through
the conference coordinators.
A live audio webcast of these presentations will also be
available by accessing DURECT's homepage at www.durect.com and
clicking "Investor Relations." If you are unable to
participate during the live webcast, the call will be archived on
DURECT's website under Audio Archive in the "Investor Relations"
section.
About DURECT Corporation
DURECT is a biopharmaceutical company actively developing new
therapeutics based on its Epigenetic Regulator Program and
proprietary drug delivery platforms. DUR-928, a new chemical
entity in Phase 1 development, is the lead candidate in DURECT's
Epigenetic Regulator Program. An endogenous, orally
bioavailable small molecule, DUR-928 has been shown in preclinical
studies to play an important regulatory role in lipid homeostasis,
inflammation, and cell survival. Human applications may
include acute organ injury, chronic metabolic diseases such as
nonalcoholic fatty liver disease (NAFLD), nonalcoholic
steatohepatitis (NASH) and other liver diseases with both broad and
orphan populations, and inflammatory skin conditions such as
psoriasis. DURECT's advanced oral, injectable, and
transdermal delivery technologies are designed to enable new
indications and enhanced attributes for small-molecule and biologic
drugs. One late-stage product candidate in this category is
POSIMIR® (SABER®-Bupivacaine), an
investigational locally-acting, non-opioid analgesic intended to
provide up to 3 days of continuous pain relief after surgery.
Another late stage product candidate is REMOXY® ER
(oxycodone), an investigational pain control drug based on DURECT's
ORADUR® technology. For more information, please
visit www.durect.com.
NOTE: POSIMIR®, SABER®, and
ORADUR® are trademarks of DURECT Corporation. Other
referenced trademarks belong to their respective owners.
POSIMIR, DUR-928, REMOXY ER and ORADUR-Methylphenidate ER are drug
candidates under development and have not been approved for
commercialization by the U.S. Food and Drug Administration or other
health authorities.
View original
content:http://www.prnewswire.com/news-releases/durect-to-participate-in-upcoming-healthcare-conferences-300514004.html
SOURCE DURECT Corporation